Helen Mary Armstrong

US Patent:

6972295, Dec 6, 2005

Filed:

Mar 12, 2003

Appl. No.:

10/387265

Inventors:

William K. Hagmann - Westfield NJ, US
Linus S. Lin - Westfield NJ, US
Shrenik K. Shah - Metuchen NJ, US
Ravindra N. Guthikonda - Edison NJ, US
Hongbo Qi - Edison NJ, US
Linda L. Chang - Wayne NJ, US
Ping Liu - Edison NJ, US
Helen M. Armstrong - Westfield NJ, US
James P. Jewell - Jersey City NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K031/4412
C07D213/70

US Classification:

514345, 546290

Abstract:

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

US Patent:

7550489, Jun 23, 2009

Filed:

Feb 1, 2008

Appl. No.:

12/012463

Inventors:

William K. Hagmann - Westfield NJ, US
Linus S. Lin - Westfield NJ, US
Shrenik K. Shah - Metuchen NJ, US
Ravindra N. Guthikonda - Edison NJ, US
Hongbo Qi - Edison NJ, US
Linda L. Chang - Wayne NJ, US
Ping Liu - Edison NJ, US
Helen M. Armstrong - Westfield NJ, US
James P. Jewell - Jersey City NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31/435

US Classification:

514354, 514355

Abstract:

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

US Patent:

7816534, Oct 19, 2010

Filed:

Apr 16, 2009

Appl. No.:

12/386336

Inventors:

William K. Hagmann - Westfield NJ, US
Linus S. Lin - Westfield NJ, US
Shrenik K. Shah - Metuchen NJ, US
Ravindra N. Guthikonda - Edison NJ, US
Hongbo Qi - Edison NJ, US
Linda L. Chang - Wayne NJ, US
Ping Liu - Edison NJ, US
Helen M. Armstrong - Westfield NJ, US
James P. Jewell - Jersey City NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/44
C07D 213/04
C07D 401/02
C07D 403/02
C07D 239/02

US Classification:

546255, 546266, 5462681, 544238, 514256, 514336, 514340

Abstract:

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

US Patent:

20050234061, Oct 20, 2005

Filed:

Apr 19, 2005

Appl. No.:

11/109076

Inventors:

William Hagmann - Westfield NJ, US
Linus Lin - Westfield NJ, US
Shrenik Shah - Metuchen NJ, US
Ravindra Guthikonda - Edison NJ, US
Hongbo Qi - Edison NJ, US
Linda Chang - Wayne NJ, US
Ping Liu - Edison NJ, US
Helen Armstrong - Westfield NJ, US
James Jewell - Jersey City NJ, US
Thomas Lanza - Edison NJ, US

International Classification:

A61K031/502
A61K031/428
A61K031/423
A61K031/4196
A61K031/405
A61K031/401
A61K031/165

US Classification:

514248000, 514367000, 514375000, 514423000, 514419000, 514617000, 514383000, 544237000, 548152000, 548217000, 548495000, 548537000

Abstract:

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

US Patent:

20070105914, May 10, 2007

Filed:

Sep 14, 2004

Appl. No.:

10/571842

Inventors:

Helen Armstrong - Westfield NJ, US
Linda Chang - Wayne NJ, US
Ravindra Guthikonda - Edison NJ, US
William Hagmann - Westfield NJ, US
Linus Lin - Westfield NJ, US
Shrenik Shah - Metuchen NJ, US

International Classification:

A61K 31/44
A61K 31/277
A61K 31/18

US Classification:

514357000, 564086000, 514602000, 514520000, 558408000, 546329000

Abstract:

The substituted sulfonamides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

US Patent:

20090197883, Aug 6, 2009

Filed:

Mar 3, 2006

Appl. No.:

11/885851

Inventors:

Helen M. Armstrong - Westfield NJ, US
Linda L. Chang - Wayne NJ, US
Richard Frenette - Laval, CA
Dwight MacDonald - I'lle Bizard, CA
Hyun O. Ok - Colonia NJ, US
Michel Therien - Laval, CA
Feroze Ujjainwalla - Scotch Plains NJ, US

International Classification:

A61K 31/5377
C07D 417/02
A61K 31/4439
C07D 401/02
A61K 31/4709
C07D 413/02
C07D 403/02
A61K 31/506
C07D 487/02
A61K 31/519
A61P 29/00
A61P 9/10

US Classification:

5142352, 5462701, 514338, 546167, 514314, 544128, 544331, 514275, 544263, 5142621

Abstract:

The instant invention provides compounds of Formula (I) which are 5-lipoxygenase activating protein inhibitors. Compounds of Formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.

US Patent:

20090258885, Oct 15, 2009

Filed:

Nov 2, 2006

Appl. No.:

12/084374

Inventors:

Helen M. Armstrong - Westfield NJ, US
Linda L. Chang - Wayne NJ, US
Lin Chu - Scotch Plains NJ, US
Rosemary Sisco - Old Bridge NJ, US
Hyun O. Ok - Colonia NJ, US
Jinyou Xu - Scotch Plains NJ, US
Feroze Ujjainwalla - Scotch Plains NJ, US

International Classification:

A61K 31/506
C07D 401/12
C07D 413/12
A61K 31/4709
A61P 9/10

US Classification:

514256, 544333, 546176, 514314

Abstract:

The instant invention provides compounds of Formula I which are 5-lipoxygenase activating protein inhibitors. Compounds of Formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents.

US Patent:

20110003815, Jan 6, 2011

Filed:

Oct 6, 2008

Appl. No.:

12/682150

Inventors:

Anthony Ogawa - Mountainside NJ, US
Feroze Ujjainwalla - Scotch Plains NJ, US
Bing Li - Towaco NJ, US
Lin Chu - Scotch Plains NJ, US
Minal Patel - Galloway NJ, US
Helen M. Armstrong - Westfield NJ, US
Hyun O. Ok - Colonia NJ, US
Rosemary Sisco - Old Bridge NJ, US
Dwight MacDonald - L'Ile Bizard, CA
John Hutchinson - La Jolla CA, US
Helene Perrier - Chatham NJ, US

International Classification:

A61K 31/5377
C07D 401/14
C07D 413/12
C07D 211/68
C07D 417/12
C07D 403/12
A61K 31/4439
A61K 31/444
A61K 31/501
A61P 9/10

US Classification:

5142362, 5462684, 5462691, 544138, 546194, 5462714, 5462687, 5462724, 5462754, 5462721, 544238, 514333, 514318, 51425205

Abstract:

The present invention provides compounds of Formula I which are FLAP inhibitors useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.